Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression

Conclusion: Mortality was high and most often unrelated to liver disease in this HIV/HBV-Coinfected cohort treated predominantly with TDF-containing HAART. Optimal CD4 counts predicted survival and the achievement of HBV virological end points. Tenofovir prevented liver decompensation but not HCC, which was the predominant cause of liver death.
Source: Journal of the International Association of Physicians in AIDS Care (JIAPAC) - Category: Infectious Diseases Authors: Tags: Viral Hepatitis Source Type: research